KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

BeOne Medicines (ONC) Gross Margin (2017 - 2025)

Historic Gross Margin for BeOne Medicines (ONC) over the last 9 years, with Q3 2025 value amounting to 86.09%.

  • BeOne Medicines' Gross Margin rose 31000.0% to 86.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 86.19%, marking a year-over-year increase of 24500.0%. This contributed to the annual value of 84.41% for FY2024, which is 1400.0% down from last year.
  • As of Q3 2025, BeOne Medicines' Gross Margin stood at 86.09%, which was up 31000.0% from 87.49% recorded in Q2 2025.
  • BeOne Medicines' 5-year Gross Margin high stood at 94.61% for Q1 2021, and its period low was 75.82% during Q2 2021.
  • For the 5-year period, BeOne Medicines' Gross Margin averaged around 82.96%, with its median value being 83.32% (2023).
  • Its Gross Margin has fluctuated over the past 5 years, first skyrocketed by 217800bps in 2021, then plummeted by -158800bps in 2022.
  • BeOne Medicines' Gross Margin (Quarter) stood at 77.31% in 2021, then grew by 4bps to 80.66% in 2022, then grew by 3bps to 83.32% in 2023, then increased by 3bps to 85.76% in 2024, then rose by 0bps to 86.09% in 2025.
  • Its Gross Margin stands at 86.09% for Q3 2025, versus 87.49% for Q2 2025 and 85.23% for Q1 2025.